Vericel Corp

About:

Vericel Corp is engaged in the development of treatments for critical cardiovascular diseases.

Website: http://vcel.com/

Twitter/X: astm4f8f1f2870

Top Investors: Eastern Capital

Description:

Vericel (formerly Aastrom Biosciences) is developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI™, a third-generation autologous chondrocyte implantation product for the treatment of focal chondral cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Total Funding Amount:

$157M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Ann Arbor, Michigan, United States

Founded Date:

1989-01-01

Contact Email:

mail(AT)vcel.com

Founders:

Bernhard Palsson

Number of Employees:

251-500

Last Funding Date:

2018-06-07

IPO Status:

Public

Industries:

© 2025 bioDAO.ai